Compare RXO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RXO | IMCR |
|---|---|---|
| Founded | 2022 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | 2021 |
| Metric | RXO | IMCR |
|---|---|---|
| Price | $14.43 | $32.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 10 |
| Target Price | $16.25 | ★ $65.33 |
| AVG Volume (30 Days) | ★ 2.0M | 284.1K |
| Earning Date | 02-04-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,940,000,000.00 | $379,590,000.00 |
| Revenue This Year | $28.02 | $32.28 |
| Revenue Next Year | $3.31 | $10.66 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.85 | 28.11 |
| 52 Week Low | $10.43 | $23.15 |
| 52 Week High | $26.92 | $40.72 |
| Indicator | RXO | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 58.96 | 33.89 |
| Support Level | $12.45 | $34.00 |
| Resistance Level | $12.87 | $34.97 |
| Average True Range (ATR) | 0.62 | 1.40 |
| MACD | 0.04 | -0.43 |
| Stochastic Oscillator | 80.60 | 4.95 |
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.